Company Profile
Rhythm Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- RYTM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
112.10 USD (+1.26%)
Close
Last updated: August 6, 2026
5.79B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RYTM closed up 1.26% at $112.10. No new same-company headline was identified in the current news window.
Company overview
Rare Neuroendocrine Diseases
Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity. Its programs focus on restoring melanocortin-4 receptor pathway signaling in genetically or structurally defined patient populations.
IMCIVREE Franchise
IMCIVREE, or setmelanotide, is an MC4R agonist approved for several forms of syndromic, monogenic and acquired hypothalamic obesity. The product is commercialized in the United States and selected international markets and is being expanded through additional regulatory submissions and clinical studies.
Acquired Hypothalamic Obesity
Following FDA and European authorization, Rhythm launched IMCIVREE in the United States for acquired hypothalamic obesity and is preparing country-level European access. A Japanese application is also under regulatory review based on the TRANSCEND program.
Lifecycle and Next-Generation Programs
The company continues to study setmelanotide in congenital hypothalamic obesity. RM-718 is a next-generation MC4R-pathway candidate in Phase 1/2 development for Prader-Willi syndrome.
Future catalysts
Japanese PMDA decision on IMCIVREE for acquired hypothalamic obesity expected in the second half of 2026, with a potential launch by year-end.
Completion of enrollment in the setmelanotide congenital hypothalamic obesity substudy expected in the second half of 2026.
Completion of enrollment in Part D of the RM-718 Phase 1/2 trial in Prader-Willi syndrome expected in the second half of 2026.
European country launches for acquired hypothalamic obesity anticipated in 2027.
Recent news
- 01
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Source: Rhythm Pharmaceuticals
- 02
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Source: Rhythm Pharmaceuticals
- 03
- 04
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Source: Rhythm Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rhythm Pharmaceuticals (RYTM)?
Rhythm Pharmaceuticals (RYTM) most recently closed at 112.10 USD, a +1.26% move versus the previous session.
What is the market cap of Rhythm Pharmaceuticals (RYTM)?
Rhythm Pharmaceuticals currently has a market capitalization of 5.79B USD on BioPharmSignal.
What does Rhythm Pharmaceuticals do?
Rare Neuroendocrine Diseases Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity. Its programs focus on restoring melanocortin-4 receptor pathway signaling in genetically or structurally defined patient populations. IMCIVREE Franchise IMCIVREE, or...
On which exchange is RYTM stock listed?
Rhythm Pharmaceuticals (RYTM) is associated with NASDAQ, United States, Biopharma.
What is RM-718?
Completion of enrollment in Part D of the RM-718 Phase 1/2 trial in Prader-Willi syndrome expected in the second half of 2026.
Which conditions is Rhythm Pharmaceuticals targeting with RM-718?
Rhythm Pharmaceuticals is associated with obesity, genetic disease based on its company overview and current catalyst commentary.
How does Rhythm Pharmaceuticals describe recent progress with RM-718?
Completion of enrollment in Part D of the RM-718 Phase 1/2 trial in Prader-Willi syndrome expected in the second half of 2026.
What is Rare?
Rare Neuroendocrine Diseases Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity.